(IN BRIEF) Basilea Pharmaceutica has initiated FORWARD‑IM, a global Phase 3 trial evaluating fosmanogepix in adults with invasive mold infections. Building on positive Phase 1 and Phase 2 results—and following the FAST‑IC Phase 3 candidemia trial—this open‑label study will randomize about 160 patients to … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Amplyx Pharmaceuticals, Aspergillus spp., BARDA, Basilea Pharmaceutica Ltd, broad‑spectrum antifungal, Candida auris, candidemia, Cresemba®, FAST‑IC, FDA Fast Track, FORWARD‑IM, fosmanogepix, Fusarium spp., HHS ASPR, invasive candidiasis, invasive mold infections, Lomentospora prolificans, Mucorales, orphan drug, Pfizer, phase 3 study, PSI CRO AG, QIDP, Zevtera®